Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company entered into an amended and restated products purchase agreement with its largest customer (the "Customer").
Under the agreement, Rockwell Medical and the Customer agreed to an increase in product pricing, effective September 1, 2023 and continuing until December 31, 2024, and a one-time payment to Rockwell on or after December 1, 2023. The Customer has the option to further extend the term through December 31, 2025. In the event of such an extension, product pricing will be increased for the extended term.
For more details about this amended and restated products purchase agreement, please reference the Form 8-K filed September 21, 2023.
https://finance.yahoo.com/news/rockwell-medical-enters-products-purchase-103000093.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.